Company / Capital Expenditures
Neurogene Inc. Capital Expenditures History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Expenditures
$808.0K
FY2025
5-year range
$321.0K / $808.0K
FY2021-FY2025
Trend
+151.7%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Capital Expenditures returned to growth in FY2025 after 2 years of decline, reaching $808,000.
Based on SEC 10-K filings.
$808,000 in FY2025.
Improved from $494,000 to $808,000 over the past 6 years.
Capital Expenditures over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, capital expenditures increased 151.7% year-over-year.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -6.24 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital ExpendituresValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $808.0K | +151.7% |
| FY2024 | $321.0K | -35.0% |
| FY2019 | $494.0K | -30.7% |
| FY2018 | $713.0K | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026